Before You Forget: The Science Behind Catching Alzheimer’s Early

For more than a decade, the detection of Alzheimer’s disease almost always arrived too late. By the time someone forgot a name, face, or route to their house, the disease had already been in the works of reshaping their brain for years and sometimes even decades. However, that reality is beginning to change with recent advancements in genetics and biomarker research that have already begun to challenge the boundaries of early detection in Alzheimer’s. But what can we do with this emerging knowledge?

The process of developing a neurodegenerative disease such as Alzheimer’s is not a sudden event, like developing the flu or breaking a bone. Instead, the damage slowly accumulates as the amyloid plaques and tau tangles build up in the brain long before any actual symptoms emerge. This process has been established for decades, yet the tools to detect these changes in living people have only recently been put to the test. Blood-based biomarker tests can now identify elevated levels of amyloid-beta and phosphorylated tau proteins years before cognitive decline begins: meaning what once required is an expensive, time-intensive PET scan or lumbar puncture can increasingly be detected through an inexpensive and routine blood draw.

The use of genetics adds another layer of precision to detecting Alzheimer’s. The APOE ε4 allele is largely known as the most significant genetic risk factor for late-onset Alzheimer’s, increasing an individual’s risk two to threshold with just one copy, and up to twelve-fold with two.  Polygenic risk scores are now being used to stratify individuals risk level before any biological warning signs appear. Although these risk scores don’t predict the development of this disease with absolute certainty, by aggregating hundreds of small genetic variants across the genome, they help identify who would benefit most from early monitoring.

The key question remains: Why does early Alzheimer’s detection matter? Most clinical trials for Alzheimer’s related therapies have historically failed, attributable to the enrollment of patients whose disease was already too advanced and developed. However, early detection allows for a critical shift in intervention timing. If an identified individual is labeled as high-risk in their 40s or 50s, lifestyle or pharmaceutical interventions can be tested and applied at a point where the brain still has capacity for resilience against the disease. Thus, the FDA approved anti-amyloid therapies lecanemab and donaemab are promising examples; they show measurable and realistic benefits, with researchers believing their effects will be amplified the earlier treatment begins. 

Still, early detection raises questions that medicine alone cannot yet answer. One learning they carry APOE ε4 or have elevated amyloid before showing any symptoms is psychologically complex; this can change how individuals perceive their futures, families, and their future choices. Thus, ethical frameworks around genetic disclosure and equitable access to testing have yet to catch up. 

But what is prominently clear is that for the first time, we have the tools to target Alzheimer’s before it arrives. For the millions of families who have sat across from someone they love and watched their memory slowly deteriorate, that matters more than any past statistic ever could.